Matches in UGent Biblio for { <https://biblio.ugent.be/publication/3194897#aggregation> ?p ?o. }
Showing items 1 to 49 of
49
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B764394.
- aggregation creator B764395.
- aggregation creator B764396.
- aggregation creator B764397.
- aggregation creator B764398.
- aggregation creator B764399.
- aggregation creator B764400.
- aggregation creator B764401.
- aggregation creator B764402.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2013".
- aggregation format "application/pdf".
- aggregation hasFormat 3194897.bibtex.
- aggregation hasFormat 3194897.csv.
- aggregation hasFormat 3194897.dc.
- aggregation hasFormat 3194897.didl.
- aggregation hasFormat 3194897.doc.
- aggregation hasFormat 3194897.json.
- aggregation hasFormat 3194897.mets.
- aggregation hasFormat 3194897.mods.
- aggregation hasFormat 3194897.rdf.
- aggregation hasFormat 3194897.ris.
- aggregation hasFormat 3194897.txt.
- aggregation hasFormat 3194897.xls.
- aggregation hasFormat 3194897.yaml.
- aggregation isPartOf urn:issn:0040-6376.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial".
- aggregation abstract "Background : Patients with severe asthma are at increased risk of exacerbations and lower respiratory tract infections (LRTI). Severe asthma is heterogeneous, encompassing eosinophilic and non-eosinophilic (mainly neutrophilic) phenotypes. Patients with neutropilic airway diseases may benefit from macrolides. Methods : We performed a randomised double-blind placebo-controlled trial in subjects with exacerbation-prone severe asthma. Subjects received low-dose azithromycin (n=55) or placebo (n=54) as add-on treatment to combination therapy of inhaled corticosteroids and long-acting beta(2) agonists for 6 months. The primary outcome was the rate of severe exacerbations and LRTI requiring treatment with antibiotics during the 26-week treatment phase. Secondary efficacy outcomes included lung function and scores on the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ). Results : The rate of primary endpoints (PEPs) during 6 months was not significantly different between the two treatment groups: 0.75 PEPs (95% CI 0.55 to 1.01) per subject in the azithromycin group versus 0.81 PEPs (95% CI 0.61 to 1.09) in the placebo group (p=0.682). In a predefined subgroup analysis according to the inflammatory phenotype, azithromycin was associated with a significantly lower PEP rate than placebo in subjects with non-eosinophilic severe asthma (blood eosinophilia <= 200/mu l): 0.44 PEPs (95% CI 0.25 to 0.78) versus 1.03 PEPs (95% CI 0.72 to 1.48) (p=0.013). Azithromycin significantly improved the AQLQ score but there were no significant between-group differences in the ACQ score or lung function. Azithromycin was well tolerated, but was associated with increased oropharyngeal carriage of macrolide-resistant streptococci. Conclusions : Azithromycin did not reduce the rate of severe exacerbations and LRTI in patients with severe asthma. However, the significant reduction in the PEP rate in azithromycin-treated patients with non-eosinophilic severe asthma warrants further study.".
- aggregation authorList BK1133473.
- aggregation endPage "329".
- aggregation issue "4".
- aggregation startPage "322".
- aggregation volume "68".
- aggregation aggregates 3194920.
- aggregation isDescribedBy 3194897.
- aggregation similarTo thoraxjnl-2012-202698.
- aggregation similarTo LU-3194897.